<\/p>\n
Aspen reported higher earnings as Africa\u2019s largest drug maker benefits from a restructuring of its manufacturing operations and expands its presence in the fast-growing market for weight-loss medicines.<\/p>\n
Normalised earnings from continuing operations rose 28% at constant exchange rates in the year through June, the company said in a statement Wednesday.<\/p>\n
Read:
Aspen joins Africa push to make MSD\u2019s once-a-month HIV prevention pill
Aspen names Ben Kruger as next chair in board overhaul<\/p>\n
Its expansion comes amid competition to capture growing demand for medicines that mimic the GLP-1 gut hormone, which suppresses appetite. The company said the rollout of this portfolio globally is expected to begin in the new financial year and contribute to growth in its commercial pharmaceuticals business.<\/p>\n
ADVERTISEMENT<\/p>\n
CONTINUE READING BELOW<\/p>\n
In South Africa, Aspen already distributes Eli Lilly & Co\u2019s blockbuster drug Mounjaro, or tirzepatide, which was launched for diabetes in December 2024 and has since been approved for chronic weight management.<\/p>\n
Novo Nordisk A\/S is seeking South African approval for an oral version of its Wegovy obesity treatment, while the expiry of the local patent covering injectable semaglutide is opening the market to cheaper alternatives.<\/p>\n
Read:\u00a0\u00a0Aspen completes Apac exit with bigger-than-expected R27bn cash windfall<\/p>\n
Aspen received Canadian regulatory approval in July for its generic injectable semaglutide for treating type 2 diabetes, although it has said commercialisation depends on supplies of the active pharmaceutical ingredient from India\u2019s Dr. Reddy\u2019s Laboratories, which has experienced temporary supply constraints.<\/p>\n
ADVERTISEMENT:<\/p>\n
CONTINUE READING BELOW<\/p>\n
Read:
Look beyond the healthcare headline
India\u2019s pharma billionaire eyes world\u2019s top insulin supplier crown<\/p>\n
The Durban, South Africa-based company separately said Wednesday that it had repurchased 13.3 million shares for about R1.98 billion ($123 million), equivalent to roughly 3% of its issued share capital at the time shareholders approved the buyback authority. The shares were bought at an average price of about R148.17 apiece from May through August.<\/p>\n
Read the Sens here.<\/p>\n
\u00a9 2026 Bloomberg<\/p>\n
#Aspen #earnings #rise #drug #maker #targets #weightloss #market<\/p>\n","protected":false},"excerpt":{"rendered":"
Aspen reported higher earnings as Africa\u2019s largest drug maker benefits from a restructuring of its…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[4174,764,1308,892,33,70,956,2814],"_links":{"self":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/15141"}],"collection":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15141"}],"version-history":[{"count":0,"href":"https:\/\/stock999.top\/index.php?rest_route=\/wp\/v2\/posts\/15141\/revisions"}],"wp:attachment":[{"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stock999.top\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}